XML 38 R21.htm IDEA: XBRL DOCUMENT
v3.22.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2021
Share-based Payment Arrangement [Abstract] |
Stock-Based Compensation | Stock-Based Compensation 2012 Stock Option Plan Effective May 1, 2012, the Company adopted the 2012 Stock Plan (the “2012 Plan”). Options granted under the 2012 Plan may be either incentive stock options or nonqualified stock options. Incentive stock options (“ISOs”) may be granted only to employees (including officers and directors). Non-qualified stock options (“NSOs”) may be granted to employees and consultants. The exercise price of ISOs and NSOs shall not be less than 100% of the estimated fair value of the common shares on the date of grant, respectively, as determined by the Company’s board of directors. The exercise price of an ISO granted to a 10% or greater stockholder shall not be less than 110% of the estimated fair value of the common shares on the date of grant. Options generally vest over a period of four years. 2021 Equity Incentive Plan In July 2021, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2021 Equity Incentive Plan (the “2021 Plan”), which became effective on July 14, 2021. The Company’s 2012 Stock Plan was terminated immediately prior to the effectiveness of the 2021 Plan. The 2021 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), to the Company’s employees and any parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), and performance awards to the Company’s employees, directors, and consultants and the Company’s parent and subsidiary corporations’ employees and consultants. Subject to the adjustment provisions of and the automatic increase described in the 2021 Plan, a total of 23,000,000 shares of the Company’s Class A common stock were reserved for issuance pursuant to the 2021 Plan, plus 36,101,718 shares of the Company’s Class A common stock reserved for future issuance under the 2012 Stock Plan. Subject to the adjustment provisions of the 2021 Plan, the number of shares available for issuance under the 2021 Plan will also include an annual increase on the first day of each fiscal year beginning on January 1, 2022, equal to the least of (a) 34,500,000 shares of Class A common stock, (b) 5% of the total number of shares of all classes of the Company’s common stock outstanding on the last day of immediately preceding fiscal year, or (c) such other amount as the Company’s board of directors (or its committee) may determine. Options granted under the 2021 Plan vest over periods ranging from one to four years. A summary of the stock option activity is as follows:
| Number of options |  | Weighted average exercise price |  | Weighted average remaining contractual life |  | Aggregate intrinsic value
| (In thousands) |  |  |  | (In years) |  | (In thousands)
Balance as of December 31, 2020 | 33,750 |  |  | $ | 1.74 |  |  | 7.95 |  | $ | 175,444 |
Granted | 13,790 |  |  | 12.29 |  |  |  |  |
Exercised | (12,988) |  |  | 1.95 |  |  |  |  |
Cancelled and forfeited | (2,877) |  |  | 6.51 |  |  |  |  |
Balance as of December 31, 2021 | 31,675 |  |  | $ | 5.81 |  |  | 8.01 |  | $ | 108,826 |
Vested and exercisable as of December 31, 2021 | 11,067 |  |  | $ | 2.18 |  |  | 6.72 |  | $ | 61,011 |
The weighted average grant-date fair value of options granted during the years ended December 31, 2021, 2020 and 2019 was $6.33, $1.86 and $1.05 per share, respectively. The total fair value of options vested during the years ended December 31, 2021, 2020 and 2019 was $17.5 million, $7.7 million and $3.1 million respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $71.6 million, $39.1 million and $5.2 million respectively. The estimated grant date fair values of the employee stock options granted under the 2012 and 2021 Plan were calculated using the Black-Scholes Merton Option pricing model, based on the following weighted average assumptions:
|  |  | Year Ended December 31,
|  |  |  |  | 2021 |  | 2020 |  | 2019
Expected term (years) |  |  |  |  | 5.93 |  | 5.90 |  | 6.24
Expected volatility |  |  |  |  | 32.85% |  | 35.14% |  | 38.83%
Risk-free interest rate |  |  |  |  | 1.04% |  | 0.58% |  | 1.97%
Expected dividend yield |  |  |  |  | — |  | — |  | —
Risk-Free Interest Rate. The risk-free interest rate is based on U.S. treasury zero-coupon issues with remaining terms similar to the expected term of the options at the date of grant. Expected Term. The expected term represents the period that the Company’s share-based awards are expected to be outstanding. The Company applies the simplified method in determining the expected life of the stock options as the Company has limited historical basis upon which to determine historical exercise periods. Expected Dividend Yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and, therefore, used an expected dividend yield of zero in the valuation model. Expected Volatility. Expected volatility of the stock is based on the average historical volatility of the Company’s peer group after consideration of their size, maturity, profitability, growth, risk, and return on investment as the Company has limited historical volatility. Fair Value. Prior to the IPO, the Company’s board of directors and in part based upon a valuation provided by a third-party valuation firm, determined the fair value of the Company’s common stock in connection with the grant of stock options and stock awards. Due to there being no public market for the Company’s common stock, its board of directors considered the third-party valuation and other factors, including but not limited to, secondary sales of the Company’s common stock, revenue growth, the current status of its operations, its financial condition, its stage of development, and its competition to establish the fair market value of the Company’s common stock at the time of grant of the stock option or stock award. For grants issued subsequent to the Company’s IPO, the Company used the closing market price of its stock on the date of grant. As of December 31, 2021, the total unrecognized stock-based compensation expense for stock options issued under the 2012 Plan and the 2021 Plan was approximately $75.0 million, which is expected to be recognized over a weighted average period of 2.9 years. Early Exercise of Common Stock Options The Company’s board of directors has authorized certain stock option holders to exercise unvested options to purchase shares of Class A common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee’s termination of service as a service provider (as defined in the 2012 Plan and the 2021 Plan), at the original issuance price, until the options are fully vested. As of December 31, 2021 and December 31, 2020, 1,819,558 and 162,317 shares of Class A common stock and pre-IPO Class B common stock, respectively, were subject to repurchase. As of December 31, 2021 and December 31, 2020, the cash proceeds received for unvested shares of Class A common stock and pre-IPO Class B common stock, respectively, recorded within Other long-term liabilities in the consolidated balance sheets were $7.0 million and $0.3 million. Restricted Stock Units A summary of the Company’s RSU activity and related information is as follows:
| Number of RSUs |  | Weighted average grant date fair value per share
| (In thousands) |  |
Balance as of December 31, 2020 | — |  |  | $ | — |
Granted | 2,717 |  |  | 9.15 |
Vested | (108) |  |  | 13.94 |
Cancelled and forfeited | (20) |  |  | 13.89 |
Balance as of December 31, 2021 | 2,589 |  |  | $ | 8.91 |
As of December 31, 2021, there was $21.0 million of unrecognized stock-based compensation expense related to unvested RSUs, which is expected to be recognized over a weighted average period of 0.6 years. RSUs granted under the 2021 Plan generally vest quarterly over a period of one year from the grant date. The total fair value of RSUs vested during the year ended December 31, 2021 was $1.5 million. Non-Plan Co-Founder and Head of Blend Options In March 2021, the Company’s board of directors granted to its Co-Founder and Head of Blend a stand-alone stock option issued outside of the 2012 Plan covering a maximum of 26,057,181 shares of Class B common stock with an exercise price of $8.58 per share. The award has a 15-year term (subject to earlier termination when shares subject to the award are no longer eligible to vest) and vests upon the satisfaction of a service condition, liquidity event-related performance condition, and performance-based market conditions. The terms of the award stipulated that if an IPO is completed within 15 months of the date of grant, the first tranche of 1,954,289 shares will vest. The remaining tranches of shares will vest dependent on performance goals tied to the Company’s stock price hurdles with specified expiration dates for each tranche. On June 30, 2021, the Company’s board of directors approved a modification to the Co-Founder and Head of Blend award related to market-based performance targets that impact the Company stock price hurdles. The impact of the modification did not result in stock-based compensation expense as of the modification date as the satisfaction of the IPO performance condition was not probable at that time. The estimated fair value of the first tranche as of the modification date was determined using Black-Scholes Merton Option pricing model, which resulted in fair value of $12.27 per share based on the following assumptions:
Fair value of common stock | $18.00
Expected term (years) | 7.44
Expected volatility | 45.00%
Risk-free interest rate | 1.71%
Expected dividend yield | —
The remaining tranches were valued using a Monte Carlo simulation model. The weighted average estimated fair value of the remaining tranches as of the modification date was $3.80 per share based on the following assumptions:
Fair value of common stock | $18.00
Remaining contractual term (years) | 14.75
Expected volatility | 40.00%
Risk-free interest rate | 1.71%
Expected dividend yield | —
In July 2021, the first tranche of 1,954,289 shares of the Co-Founder and Head of Blend stock option award vested upon completion of the IPO. Upon the completion of the IPO, the Company recognized $24.0 million in stock-based compensation expense related to this tranche, and additional catch up expense of $5.7 million related to the remaining tranches. The total stock-based compensation expense recognized for this award for the year ended December 31, 2021 was $38.8 million. The total unrecognized compensation expense related to the award for all tranches was $46.0 million as of December 31, 2021, which will be recognized over an estimated weighted average remaining period of 3.4 years. Stock-Based Compensation Expense The Company’s stock-based compensation expense was as follows:
|  |  | Year Ended December 31,
|  |  |  |  | 2021 |  | 2020 |  | 2019
|  |  |  |  | (In thousands)
Cost of revenue |  |  |  |  | $ | 753 |  |  | $ | 79 |  |  | $ | 46 |
Research and development |  |  |  |  | 13,184 |  |  | 4,250 |  |  | 3,431 |
Sales and marketing |  |  |  |  | 7,167 |  |  | 3,675 |  |  | 966 |
General and administrative |  |  |  |  | 49,740 |  |  | 2,120 |  |  | 5,446 |
Total |  |  |  |  | $ | 70,844 |  |  | $ | 10,124 |  |  | $ | 9,889 |
Included in stock-based compensation expense are amounts related to the sale of employee stock on the secondary market to existing investors at a price above fair market value at the time of the sale. Stock-based compensation related to the secondary sales, which represents the amount paid to purchase shares of the Company’s common stock in excess of fair value, was as follows:
|  |  | Year Ended December 31,
|  |  |  |  | 2021 |  | 2020 |  | 2019
|  |  |  |  | (In thousands)
Research and development |  |  |  |  | $ | 325 |  |  | $ | 1,524 |  |  | $ | 1,694 |
Sales and marketing |  |  |  |  | 300 |  |  | 1,607 |  |  | 96 |
General and administrative |  |  |  |  | 166 |  |  | 325 |  |  | 4,372 |
Total |  |  |  |  | $ | 791 |  |  | $ | 3,456 |  |  | $ | 6,162 |
Tender Offer In January 2021, the Company’s board of directors approved a third-party tender offer, which allowed for eligible option holders and stockholders to sell shares of capital stock to the Series G investors. The third-party tender offer was completed in March 2021, in which an aggregate of 442,469 shares of common stock and Convertible Preferred Stock were purchased from participating stockholders and option holders. There was no stock-based compensation recognized related to such third-party tender offer as the purchase price was lower than the fair value at the time of the tender offer closing. Employee Note In November 2018, an executive was issued a partial-recourse promissory note (the “Employee Note”) in the amount of $2.7 million in order to exercise a stock-based compensation award for 4,000,000 shares subject to vesting conditions. The Employee Note had a maturity date of November 19, 2025 and bore an interest rate of 3.04% per annum. The employee had the right to prepay the Employee Note at any time, without penalty. The Company recorded $2.7 million as contra-equity in 2018. On June 17, 2021, the Employee Note was repaid in full, inclusive of the principal amount and accrued interest of approximately $2.9 million, and there were no shares of common stock remaining related to this award that were subject to vesting conditions as of December 31, 2021.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration